Role of Axillary Clearance After a Tumor-Positive Sentinel Node in the Administration of Adjuvant Therapy in Early Breast Cancer

被引:135
|
作者
Straver, Marieke E.
Meijnen, Philip
van Tienhoven, Geertjan
van de Velde, Cornelis J. H.
Mansel, Robert E.
Bogaerts, Jan
Demonty, Gaston
Duez, Nicole
Cataliotti, Luigi
Klinkenbijl, Jean
Westenberg, Helen A.
van der Mijle, Huub
Hurkmans, Coen
Rutgers, Emiel J. T. [1 ]
机构
[1] Netherlands Canc Inst, Dept Surg Oncol, NL-1066 CX Amsterdam, Netherlands
关键词
POSTOPERATIVE RADIOTHERAPY; OPERABLE CANCER; TRIAL; VALIDATION; WOMEN; CHEMOTHERAPY; DISSECTION; SIGNATURE; TAMOXIFEN; CONSENSUS;
D O I
10.1200/JCO.2008.21.7554
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The After Mapping of the Axilla: Radiotherapy or Surgery? (AMAROS) phase III study compares axillary lymph node dissection (ALND) and axillary radiation therapy (ART) in early breast cancer patients with tumor-positive sentinel nodes. In the ART arm, the extent of nodal involvement remains unknown, which could have implications on the administration of adjuvant therapy. In this preliminary analysis, we studied the influence of random assignment to ALND or ART on the choice for adjuvant treatment. Patients and Methods In the first 2,000 patients enrolled in the AMAROS trial, we analyzed the administration of adjuvant systemic therapy. Multivariate analysis was used to assess variables affecting the administration of adjuvant chemotherapy. Adjuvant therapy was applied according to institutional guidelines. Results Of 2,000 patients, 566 patients had a positive sentinel node and were treated per random assignment. There was no significant difference in the administration of adjuvant systemic therapy. In the ALND and ART arms, 58% (175 of 300) and 61% (162 of 266) of the patients, respectively, received chemotherapy. Endocrine therapy was administered in 78% (235 of 300) of the patients in the ALND arm and in 76% (203 of 266) of the patients in the ART arm. Treatment arm was not a significant factor in the decision, and no interactions between treatment arm and other factors were observed. Multivariate analysis showed that age, tumor grade, multifocality, and size of the sentinel node metastasis significantly affected the administration of chemotherapy. Within the ALND arm, the extent of nodal involvement remained not significant in a sensitivity multivariate analysis. Conclusion Absence of knowledge regarding the extent of nodal involvement in the ART arm appears to have no major impact on the administration of adjuvant therapy.
引用
收藏
页码:731 / 737
页数:7
相关论文
共 50 条
  • [1] Role of axillary clearance for patients with sentinel node-positive early breast cancer
    Benson, J. R.
    Wishart, G. C.
    BRITISH JOURNAL OF SURGERY, 2011, 98 (11) : 1499 - 1500
  • [2] Axillary Clearance Following Positive Sentinel Lymph Node Biopsy in Symptomatic Breast Cancer
    Shaker, Hudhaifah
    Mahate, Zeinab
    Dabritz, Grit
    Absar, Mohammed S.
    IN VIVO, 2020, 34 (06): : 3503 - 3509
  • [3] Axillary Recurrence After a Tumor-Positive Sentinel Lymph Node Biopsy Without Axillary Treatment: A Review of the Literature
    Francissen, Claire M. T. P.
    Dings, Pim J. M.
    van Dalen, Thijs
    Strobbe, Luc J. A.
    van Laarhoven, Hanneke W. M.
    de Wilt, Johannes H. W.
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (13) : 4140 - 4149
  • [4] Is axillary lymph node clearance required in node-positive breast cancer?
    Bundred, Nigel J.
    Barnes, Nicola L. P.
    Rutgers, Emiel
    Donker, Mila
    NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (01) : 55 - 61
  • [5] International multicenter tool to predict the risk of four or more tumor-positive axillary lymph nodes in breast cancer patients with sentinel node macrometastases
    Meretoja, Tuomo J.
    Audisio, R. A.
    Heikkila, P. S.
    Bori, R.
    Sejben, I.
    Regitnig, P.
    Luschin-Ebengreuth, G.
    Zgajnar, J.
    Perhavec, A.
    Gazic, B.
    Lazar, G.
    Takacs, T.
    Kovari, B.
    Saidan, Z. A.
    Nadeem, R. M.
    Castellano, I.
    Sapino, A.
    Bianchi, S.
    Vezzosi, V.
    Barranger, E.
    Lousquy, R.
    Arisio, R.
    Foschini, M. P.
    Imoto, S.
    Kamma, H.
    Tvedskov, T. F.
    Jensen, M. -B.
    Cserni, G.
    Leidenius, M. H. K.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 138 (03) : 817 - 827
  • [6] The Value of Level III Clearance in Patients With Axillary and Sentinel Node Positive Breast Cancer
    Dillon, Mary F.
    Advani, Vriti
    Masterson, Catherine
    O'Loughlin, Christina
    Quinn, Cecily M.
    O'Higgins, Niall
    Evoy, Denis
    McDermott, Enda W.
    ANNALS OF SURGERY, 2009, 249 (05) : 834 - 839
  • [7] Axillary Recurrence after Sentinel Lymph Node Biopsy for Breast Cancer
    Dauphine, Christine
    Nemtsev, Denis
    Rosing, David
    Vargas, Hernan I.
    AMERICAN SURGEON, 2010, 76 (10) : 1127 - 1129
  • [8] Nonsentinel Axillary Lymph Node Status in Clinically Node-Negative Early Breast Cancer After Primary Systemic Therapy and Positive Sentinel Lymph Node: A Predictive Model Proposal
    Cebrecos, Isaac
    Mension, Eduard
    Alonso, Inmaculada
    Castillo, Helena
    Sanfeliu, Esther
    Vidal-Sicart, Sergi
    Ganau, Sergi
    Vidal, Maria
    Schettini, Francesco
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (08) : 4657 - 4668
  • [9] Omission of Axillary Dissection in Node Positive Breast Cancer After Neoadjuvant Systemic Therapy
    Peery, Gray B.
    Pak, Joyce
    Burkbauer, Laura
    Agala, Chris B.
    Selfridge, Julia M.
    Gallagher, Kristalyn K.
    Spanheimer, Philip M.
    JOURNAL OF SURGICAL RESEARCH, 2023, 292 : 247 - 257
  • [10] Axillary management in early breast cancer with onset surgical management and positive sentinel lymph node
    Rebaza Vasquez, Lia Pamela
    Ponce de la Torre, Jaime
    Alarco, Raul
    Ayala Moreno, Joseana
    Gomez Moreno, Henry
    ECANCERMEDICALSCIENCE, 2021, 15